Agios Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion for the new indication for Pyrukynd… read more.
MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that two abstracts highlighting data on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as… read more.
Novartis presented new Pluvicto(lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2025…. read more.
Novartis announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta (iptacopan) in adults living with IgA nephropathy (IgAN). Fabhalta, an oral alternative complement pathway inhibitor,… read more.
Moderna, Inc. (announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations… read more.
Precigen Inc. announced long-term follow-up data demonstrating durable responses to Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). These data were presented at… read more.
Gilead Sciences, Inc. will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV,… read more.
AbbVie announced the FDA approval of a supplemental new drug application (sNDA) that updates the indication statement for Rinvoq (upadacitinib) for the treatment of adults with moderately to… read more.
Nuvectis Pharma Inc, a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,… read more.
Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced that a presentation related to Peyronie’s disease, or PD, and Xiaflex (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will… read more.
Actinium Pharmaceuticals, Inc.), a leader in the development of differentiated targeted radiotherapies announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer (NSCLC)… read more.
MannKind Corporation announced that the FDA has accepted the supplemental biologics license application (sBLA) seeking approval for Afrezza (insulin human) Inhalation Powder in children and adolescents living with… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
